{"url_path":"/sec/huma/8-k/2026-06-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1818382/0001104659-26-072980-index.html","accession_number":"0001104659-26-072980","cik":"0001818382","ticker":"HUMA","issuer_name":"Humacyte, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1818382/0001104659-26-072980-index.html","primary_entity_key":"0001818382","primary_entity_name":"Humacyte, Inc."},"word_count":112,"has_tables":true,"body_markdown":"**Item 7.01. Regulation FD Disclosure.**\n\n \n\nOn\nJune 10, 2026, the Company issued press releases announcing the commencement of the Offering and the pricing of the Offering. Copies\nof the press releases are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated\nby reference herein.\n\n \n\nThe information contained in this Item 7.01 shall\nnot be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),\nor incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific\nreference in such a filing.\n\n \n\n1"}